Francesca L. Maclean

Francesca L. Maclean

Auto-generated profile, based on publicly available information

Francesca L. Maclean

Research School of Engineering, the Australian National University , Canberra, Australia

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

10 April 2014 in Journal of Neurochemistry
Verified
Journal Article
Closed access
PDF file
CLChew L. Lau
Chew L. Lau
MKMichelle Kovacevic
Michelle Kovacevic
TTTine S. Tingleff
Tine S. Tingleff
JFJohn S. Forsythe
John S. Forsythe
HCHolly Cate
Holly Cate
PBPhilip M. Beart
Philip M. Beart

18 November 2015 in Stem Cells and Development
Verified
Journal Article
Closed access
FMFrancesca L. Maclean
Francesca L. Maclean
ARAlexandra L. Rodriguez
Alexandra L. Rodriguez
CPClare L. Parish
Clare L. Parish
Richard WilliamsRichard Williams
Richard Williams
David NisbetDavid Nisbet
David Nisbet
The central nervous system has a limited capacity to regenerate, and thus, traumatic injuries or diseases often have devastating consequences. Therefore, there is a distinct need to develop alternative treatments that can achieve functional recovery without side effects currently observed with some pharmacological treatments. Combining biomaterials with pluripotent stem cells (PSCs), either embryonic or induced, has the potential to revolutionize the treatment of neurodegenerative diseases and traumatic injuries. Biomaterials can mimic the extracellular matrix and present a myriad of relevant biochemical cues through rational design or further functionalization. Biomaterials such as nanofibers and hydrogels, including self-assembling peptide (SAP) hydrogels can provide a superior cell culture environment. When these materials are then combined with PSCs, more accurate drug screening and disease modeling could be developed, and the generation of large number of cells with the appropriate phenotype can be achieved, for subsequent use in vitro. Biomaterials have also been shown to support endogenous cell growth after implantation, and, in particular, hydrogels and SAPs have effectively acted as cell delivery vehicles, increasing cell survival after transplantation. Few studies are yet to fully exploit the combination of PSCs and innovative biomaterials; however, initial studies with neural stem cells, for example, are promising, and, hence, such a combination for use in vitro and in vivo is an exciting new direction for the field of neural regeneration.

20 February 2015 in Frontiers in Neuroscience
Verified
Journal Article
Open access
PDF file
RORoss O'Shea
Ross O'Shea
CLChew L. Lau
Chew L. Lau
NZNatasha Zulaziz
Natasha Zulaziz
FMFrancesca L. Maclean
Francesca L. Maclean
David NisbetDavid Nisbet
David Nisbet
PBPhilip M. Beart
Philip M. Beart
Astrocytes provide trophic, structural and metabolic support to neurons, and are considered genuine targets in regenerative neurobiology, as their phenotype arbitrates brain integrity during injury. Inhibitors of Rho kinase (ROCK) cause stellation of cultured 2D astrocytes, increased L-glutamate transport, augmented G-actin, and elevated expression of BDNF and anti-oxidant genes. Here we further explored the signposts of a cytotrophic, “healthy” phenotype by data-mining of our astrocytic transcriptome in the presence of Fasudil. Gene expression profiles of motor and autophagic cellular cascades and inflammatory / angiogenic responses were all inhibited, favouring adoption of an anti-migratory phenotype. Like ROCK inhibition, tissue engineered bioscaffolds can influence the extracellular matrix. We built upon our evidence that astrocytes maintained on 3D poly-Ɛ-caprolactone (PCL) electrospun scaffolds adopt a cytotrophic phenotype similar to that produced by Fasudil. Using these procedures, employing mature 3D cultured astrocytes, Fasudil (100 µM) or Y27632 (30 µM) added for the last 72 h of culture altered arborization, which featured numerous additional minor processes as shown by GFAP and AHNAK immunolabelling. Both ROCK inhibitors decreased F-actin, but increased G-actin labelling, indicative of disassembly of actin stress fibres. ROCK inhibitors provide additional beneficial effects for bioengineered 3D astrocytes, including enlargement of the overall arbour. Potentially, the combined strategy of bio-compatible scaffolds with ROCK inhibition offers unique advantages for the management of glial scarring. Overall these data emphasize that manipulation of the astrocyte phenotype to achieve a “healthy biology” offers new hope for the management of inflammation in neuropathologies.